Fulltext search has been disabled for Key Event Relationships (KERs) at this time. If you need this feature, send an email to aopwiki@googlegroups.com

Queries Key Event Relationship (KER) titles
Filter by Upstream Key Event title
Filter by Downstream Key Event title
Filter by AOP title

Showing 76 to 100 of 3131 KERs

Clear Table Filters
ID Upstream Event Downstream Event Creation Date Last Updated AOPs
213 195: Inhibition, NMDARs 52: Decreased, Calcium influx Nov 29, 2016 Apr 7, 2018
214 195: Inhibition, NMDARs 341: Impairment, Learning and memory Nov 29, 2016 Dec 3, 2016 None
215 195: Inhibition, NMDARs 191: Neuronal dysfunction Nov 29, 2016 Dec 3, 2016 None
228 201: Binding of antagonist, NMDA receptors 341: Impairment, Learning and memory Nov 29, 2016 Dec 3, 2016 None
229 201: Binding of antagonist, NMDA receptors 195: Inhibition, NMDARs Nov 29, 2016 Jun 13, 2018
236 209: Peptide Oxidation 134: Increase, Kupffer cell activation Nov 29, 2016 Dec 3, 2016 None
242 213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin 21: Altered regulation, Alpha hemoglobin Nov 29, 2016 Dec 3, 2016
243 213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin 118: Formation, Formation of hemoglobin adducts Nov 29, 2016 Dec 3, 2016
245 213: N/A, Parent compound is converted to the reactive metabolite and forms free radicals leadin 250: Damaging, Red blood cells; hemolysis Nov 29, 2016 Dec 3, 2016
248 214: Bile accumulation, Pathological condition 288: Activation of specific nuclear receptors, Transcriptional change Nov 29, 2016 Dec 3, 2016
252 219: Reduction, Plasma 17beta-estradiol concentrations 285: Reduction, Vitellogenin synthesis in liver Nov 29, 2016 Mar 20, 2017
253 219: Reduction, Plasma 17beta-estradiol concentrations 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Nov 29, 2016 Nov 29, 2016 None
254 220: Increase, Plasma vitellogenin concentrations 252: Increase, Renal pathology due to VTG deposition Nov 29, 2016 Jun 24, 2024
255 221: Reduction, Plasma vitellogenin concentrations 309: Reduction, Vitellogenin accumulation into oocytes and oocyte growth/development Nov 29, 2016 Mar 20, 2017
257 231: Decreased, PPAR-alpha activation 140: Decreased, HSD17B10 expression Nov 29, 2016 Dec 3, 2016
259 232: Decreased, PPAR-beta activation 140: Decreased, HSD17B10 expression Nov 29, 2016 Dec 3, 2016
260 233: Decreased, PPAR-gamma activation 140: Decreased, HSD17B10 expression Nov 29, 2016 Dec 3, 2016
261 238: Induction, Pre-mature molting 328: Decrease, Fecundity Nov 29, 2016 Dec 3, 2016 None
262 238: Induction, Pre-mature molting 350: Increase, Mortality Nov 29, 2016 Dec 3, 2016 None
263 238: Induction, Pre-mature molting 351: Increased Mortality Nov 29, 2016 Dec 3, 2016 None
266 240: Feminisation or incomplete development, Primary and accessory male sex organs 337: N/A, Impairment of reproductive capacity Nov 29, 2016 Dec 3, 2016
268 243: Reduction, Prostaglandin E2 concentration 119: N/A, Gap Nov 29, 2016 Dec 3, 2016
269 244: Alkylation, Protein 55: Cell injury/death Nov 29, 2016 Nov 29, 2016
271 244: Alkylation, Protein 209: Peptide Oxidation Nov 29, 2016 Dec 3, 2016 None
272 246: Increase, RBC congestion in liver 173: N/A, Methemoglobinemia, decreased hemoglobin, hematocrit, red blood cell number Nov 29, 2016 Dec 3, 2016